Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma

被引：0
|
作者：
Franck Morschhauser
Martin J. S. Dyer
Harriet S. Walter
Alexey V. Danilov
Loic Ysebaert
Daniel James Hodson
Christopher Fegan
Simon A. Rule
John Radford
Guillaume Cartron
Krimo Bouabdallah
Andrew John Davies
Stephen Spurgeon
Nishanthan Rajakumaraswamy
Biao Li
Rita Humeniuk
Xi Huang
Pankaj Bhargava
Juliane M. Jürgensmeier
Gilles Salles
机构：
[1] GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées,Univ. Lille, CHU Lille, ULR 7365
[2] University of Leicester,Ernest and Helen Scott Haematological Research Institute
[3] City of Hope National Medical Center,WT
[4] Département d’Hématologie IUCT-Oncopole,MRC Stem Cell Institute
[5] University of Cambridge,Department of Clinical Hematology
[6] University Hospital of Wales,Hematology Clinic
[7] University of Plymouth Medical School,Cancer Research UK Centre
[8] University of Manchester and The Christie NHS Foundation Trust,Knight Cancer Institute
[9] University Hospital of Montpellier and UMR-CNRS 5535,Hospices Civils de Lyon, Department of Hematology
[10] University Hospital of Bordeaux,undefined
[11] University of Southampton,undefined
[12] Oregon Health and Science University,undefined
[13] Gilead Sciences,undefined
[14] Inc,undefined
[15] Université de Lyon,undefined
来源：
Leukemia | 2021年 / 35卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2108 / 2113
页数：5
相关论文
共 50 条
  • [21] A Phase 1B Study of CC-122 in Combination with Obinutuzumab (GA101) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Indolent Non-Hodgkin Lymphoma
    Michot, Jean-Marie
    Doorduijn, Jeanette K.
    Bouabdallah, Reda
    Vitolo, Umberto
    Zinzani, Pier Luigi
    Kersten, Marie Jose
    Chiappella, Annalisa
    Sarmiento, Rafael
    Zuraek, Marlene
    Pourdehnad, Michael
    Hege, Kristen
    Nikolova, Zariana
    Ribrag, Vincent
    BLOOD, 2016, 128 (22)
  • [22] Phase 1b Study of PD-1 Blockade with Pembrolizumab in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
    Zinzani, Pier Luigi
    Ribrag, Vincent
    Moskowitz, Craig H.
    Michot, Jean-Marie
    Kuruvilla, John
    Balakumaran, Arun
    Snyder, Ellen
    Marinello, Patricia
    Shipp, Margaret A.
    Armand, Philippe
    BLOOD, 2015, 126 (23)
  • [23] Copanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma: A Phase II Study
    Bennani, N. Nora
    Atherton, Pamela
    Steinert, Kimberly O.
    Rimsza, Lisa M.
    Tun, Aung M.
    Hoffmann, Marc S.
    Narkhede, Mayur S.
    Vaidya, Rakhee
    Said, Rabih
    Shapiro, Geoffrey I.
    Costello, Brian A.
    Ansell, Stephen M.
    Nowakowski, Grzegorz S.
    BLOOD, 2023, 142
  • [24] Copanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma: A Phase 2 Study
    Bennani, N. Nora
    Nowakowski, Grzegorz
    Rimsza, Lisa M.
    Adjei, Alex A.
    Doyle, Laurence
    Ansell, Stephen M.
    BLOOD, 2019, 134
  • [25] Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma
    Dickinson, Michael
    Briones, Javier
    Herrera, Alex F.
    Gonzalez-Barca, Eva
    Ghosh, Nilanjan
    Cordoba, Raul
    Rutherford, Sarah C.
    Bournazou, Eirini
    Labriola-Tompkins, Emily
    Franjkovic, Izolda
    Chesne, Evelyne
    Brouwer-Visser, Jurriaan
    Lechner, Katharina
    Brennan, Barbara
    Nueesch, Eveline
    DeMario, Mark
    Ruettinger, Dominik
    Kornacker, Martin
    Hutchings, Martin
    BLOOD ADVANCES, 2021, 5 (22) : 4762 - 4770
  • [26] Phase 1b Dose-finding Study of Venetoclax With Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
    Petrillo, Alessandra
    Ip, Andrew
    Della Pia, Alexandra
    Gill, Sarvainder
    Zenreich, Joshua
    Gutierrez, Martin
    McNeill, Ann
    Feldman, Tatyana
    Leslie, Lori A.
    Goy, Andre
    HEMASPHERE, 2022, 6 (06):
  • [27] A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphoma
    Park, Steven I.
    Grover, Natalie S.
    Olajide, Oludamilola
    Asch, Adam S.
    Wall, James G.
    Richards, Kristy L.
    Sobol, Anna L.
    Deal, Allison M.
    Ivanova, Anastasia
    Foster, Matthew C.
    Muss, Hyman B.
    Shea, Thomas C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 175 (02) : 281 - 289
  • [28] A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
    Tuscano, Joseph M.
    Maverakis, Emanual
    Groshen, Susan
    Tsao-Wei, Denice
    Luxardi, Guillaume
    Merleev, Alexander A.
    Beaven, Anne
    DiPersio, John F.
    Popplewell, Leslie
    Chen, Robert
    Kirschbaum, Mark
    Schroeder, Mark A.
    Newman, Edward M.
    CLINICAL CANCER RESEARCH, 2019, 25 (23) : 7004 - 7013
  • [29] A Multicenter, Open-Label, Phase 1b/2 Study to Evaluate the Effects of Maplirpacept in Combination with Tafasitamab and Lenalidomide in People with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Hoyle, Margaret
    Paccagnella, Luisa
    BLOOD, 2023, 142
  • [30] The combination of chidamide with the CHOEP regimen in previously untreated patients with peripheral T-cell lymphoma: a prospective, multicenter, single arm, phase 1b/2 study
    Wei Zhang
    Liping Su
    Lihong Liu
    Yuhuan Gao
    Quanshun Wang
    Hang Su
    Yuhuan Song
    Huilai Zhang
    Jing Shen
    Hongmei Jing
    Shuye Wang
    Xinan Cen
    Hui Liu
    Aichun Liu
    Zengjun Li
    Jianmin Luo
    Jianxia He
    Jingwen Wang
    OAOConnor
    Daobin Zhou
    Cancer Biology & Medicine, 2021, 18 (03) : 841 - 848
12345